Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
October 04 2017 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that Dr. Joseph
Stauffer, Chief Medical Officer, will present previously announced
results from the Phase 2b trial of Oral CR845 in patients with
osteoarthritis of the knee or hip at the Janney Montgomery Scott
Osteoarthritis Pain Conference on Wednesday, October 11, 2017, at
11:15 a.m. ET in New York.
To access a live webcast of the presentation,
follow the link
below:https://cc.callinfo.com/registration/#/?meeting=1bz6od0w77fq9&campaign=12mx4sd7oz45k
An audio recording of the presentation will be available by
telephone:
- U.S. & Canada Toll-Free Dial-In: 1-877-256-3251
- U.K. Dial-In: +44 080-0692-2011
- Local Toll-Free Dial-In: 1-212-231-2921
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates, led
by CR845, that target the body's peripheral nervous system. CR845
has demonstrated initial efficacy in patients with
moderate-to-severe pain, without inducing many of the undesirable
side effects typically associated with currently available pain
therapeutics. In patients with moderate-to-severe CKD-associated
pruritus, CR845 has demonstrated its potential to reduce itch and
improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern
Investor Relations, Inc. 212-362-1200 michael@sternir.com
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024